- Home
- KTF vs GNLX Comparison
KTF vs GNLX Comparison
Compare KTF & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KTF | GNLX |
|---|---|---|
| Founded | 1988 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 365.1M | 202.4M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | KTF | GNLX |
|---|---|---|
| Price | $9.08 | $4.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.75 |
| AVG Volume (30 Days) | 103.3K | ★ 104.6K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 3.54% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.40 | $1.99 |
| 52 Week High | $9.12 | $8.54 |
Technical Indicators
Market Signals| Indicator | KTF | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 45.79 | 47.63 |
| Support Level | $9.00 | $4.21 |
| Resistance Level | $9.10 | $4.46 |
| Average True Range (ATR) | 0.06 | 0.24 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 48.84 | 88.52 |
Price Performance
Historical ComparisonAbout KTF DWS Municipal Income Trust
DWS Municipal Income Trust is a closed-ended fixed income mutual fund launched and managed by Deutsche Investment Management Americas, Inc. The company invests in the fixed income markets of the United States. The fund invests in investment-grade tax-exempt municipal securities which are exempt from federal income tax. The fund benchmarks the performance of its portfolio against the Barclays Municipal Bond Index. The Fund invests in various states, such as Texas, Florida, Pennsylvania, Illinois, and California.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.